Business
PDS to License Novel Proteins for Flu Vaccine
PDS to License Novel Proteins for Flu Vaccine.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9453Q\n NetScientific PLC\n 01 November 2021\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\", the \"Group\" or the \"Company\")\n \n \n \n \n \n PDS to \n \n License Novel Proteins for Flu Vaccine\n \n \n \n \n \n \n PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Flu Vaccine\n \n \n \n \n \n \n \n \n London, UK - 01 November 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced an agreement to license COBRA (Computationally Optimized Broadly Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its infectious disease immunotherapy pipeline, PDS0202, a universal flu vaccine candidate.\n \n \n \n \n Designed by renowned influenza expert, Dr. Ted Ross at the University of Georgia, the novel COBRA antigens are to be used in combination with Versamune® for PDS0202 for the universal prevention of infection by multiple strains of influenza virus. The antigens were selected following successful pre-clinical development work completed under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to progress PDS0202 development. PDS0202 leverages Versamune®'s ability to induce the immune system to generate high levels of flu-specific neutralizing antibodies, CD4 helper and CD8 killer T-cells, as well as long-acting memory T-cells to potentially provide broad and long-term protection against multiple influenza strains. Influenza is estimated to result in about 3 to 5 million cases of severe illness and about 290,000 to 650,000 respiratory deaths globally each year.\n \n \n \n \n \n \n PDS Biotech CEO, Frank Bedu-Addo commented:\n \n \n \"Our new agreement with the University of Georgia demonstrates the versatility and potential of our Versamune® platform and advances our infectious disease pipeline.\n \n \n \n \n \n \n \"There are four types of seasonal influenza viruses, and a universal flu vaccine would eliminate the need to manufacture a new seas...